Omega-3 fatty acids improve quality of life, outcomes in cancer
the ONA take:
According to a new study published online ahead of print in the Journal of Parenteral and Enteral Nutrition (JPEN), researchers at the University Hospitals of Leicester in the United Kingdom have found that the addition of omega-3 fatty acids to anti-cancer medications may improve quality of life and treatment outcomes in patients with cancer.
For the study, researchers enrolled 150 patients with advanced pancreatic cancer. Participants received gemcitabine 1,000 mg weekly followed by up to 100 g of omega-3 rich lipid emulsion for 3 weeks followed by 1 rest week. Patients received up to six cycles until disease progression, unacceptable toxicity, patient request, or death.
Results showed that patients who received omega-3 fatty acids experienced an improvement in response activity and disease stabilization rates, a reduction in liver metastases volume, and improved quality of life.
The findings suggest that further investigation is warranted to evaluate the addition of omega-3 fatty acids with a chemotherapy agent in a randomized phase III trial.
Addition of omega-3 fatty acids to anti-cancer medications may improve quality of life and treatment outcomes in patients with cancer.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|